▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2553 by analyst upside · 2026-06-27
EWTX
Edgewise Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+16.2%
implied upside to consensus target
Current Price $41.46
Consensus Target $48.17
Bull Target $66.0
Bear Target $30.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
7
Hold
2
Sell
0
52-Week Low $12.3
52-Week High $43.93
YTD Return +74.6%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -29.1x
EPS (TTM) $-1.66
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $12.3
52-Week High $43.93
Current Price $41.46
Bear Target $30.0
Bull Target $66.0
● Now $41.46 ● Target $48.17
TRADING DATA
Avg Volume 1.4M
YTD Return +74.6%
Analyst Count 12
Consensus Buy
Upside to Target +16.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Edgewise Therapeutics, Inc. (EWTX) is currently trading at $41.46 with a Wall Street consensus price target of $48.17, implying potential upside of 16.2% over the next 12 months. 12 analysts currently cover EWTX, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $66.0, while the most cautious has a target of $30.0.

EWTX operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 74.6% year-to-date and is currently trading near the upper end of its 52-week range of $12.3 – $43.93.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
INDV +21.2%
Indivior Pharmaceuticals, Inc.
$5B · P/E 21.2x · Buy
DOCS +21.7%
Doximity, Inc.
$4B · P/E 20.3x · Buy
CON +4.4%
Concentra Group Holdings Parent, Inc.
$4B · P/E 21.7x · Buy
CPRX +0.5%
Catalyst Pharmaceuticals, Inc.
$4B · P/E 18.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for EWTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital — Reiterated
Outperform → Outperform 2026-06-17 Building track record
Goldman Sachs — Reiterated
Neutral → Neutral 2026-06-17 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-06-16 31% win rate (48 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-02 31% win rate (48 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-06-02 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-06-02 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-03-17 43% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-03-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
20/30
Consensus clarity
13/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →